VX1.DE • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold VX1.DE in your mock portfolio yet.
The valuation and earnings metrics point to a profitable, mature biopharma with solid earnings power. A PE of 33.55 on EPS of 11.85 suggests the market is willing to pay a premium for Vertex’s earnings durability and pipeline, consistent with strong historical profitability in cystic fibrosis and expectations for future growth. While no detailed income statement is provided, the combination of positive EPS and premium multiple indicates healthy margins and return profile relative to many peers.
The stock trades at €397.55, modestly above its 200-day moving average of €374.99 and up 3.4% over the last month, indicating a constructive intermediate-term trend. An RSI of 57.32 is in neutral-to-positive territory, suggesting upward momentum without being overbought. Overall, the technical picture leans bullish but not euphoric, leaving room for further upside if fundamentals continue to support the move.
Alternative data for Vertex is broadly stable with mild positive signals but no strong inflection points. Website traffic at ~340k monthly visitors and 381 job openings (down 1.3% MoM) suggest a steady, mature operation rather than aggressive expansion. Social media presence is large and generally growing modestly across most platforms, indicating sustained brand and employer interest but not a major sentiment surge.
Combining fundamentals, valuation, and technicals, the overall picture for Vertex Pharmaceuticals Incorporated appears bullish. Profitable operations with a premium earnings multiple, a price trending above the 200-day moving average, and constructive but not overextended momentum support a positive outlook, while alternative data is broadly stable and does not contradict the bullish thesis.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: